# Safety Verification Report (50 Random Drugs)

> **Comparison**: Database Extracted Data vs Original PDF Text

## Idelalisib (Page 529)
### 1. Database (Raw Text)
```text
GFR (mL/min)
30–50 Dose as in normal renal function.
10–30 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Unlikely to be dialysed. Dose as in
normal renal function.
HD Unlikely to be dialysed. Dose as in
normal renal function.
HDF/High flux Unknown dialysability. Dose as in
normal renal function.
CAV/VVHD Unknown dialysability. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 30–50**: Dose as in normal renal function.
- **GFR 10–30**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. HD Unlikely to be dialysed. Dose as in normal renal function. HDF/High flux Unknown dialysability. Dose as in normal renal function. CAV/VVHD Unknown dialysability. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) — 30–50 Dose as in normal renal function. 10–30 Dose as in normal renal function. Other information <10 Dose as in normal renal function. • A study of pharmacokinetics and safety of idelalisib was performed in healthy subjects and subjects with severe renal impairment (estimated CRCL=15–29 mL/min). Following a single 150 mg dose, no clinically relevant changes in exposures to idelalisib or GS-563117 were observed in subjects with severe renal impairment compared to healthy subjects....

---
## Decitabine 293 (Page 312)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function. Use
with caution.
10–20 Dose as in normal renal function. Use
with caution.
<10 Dose as in normal renal function. Use
with caution.
APD/CAPD Possibly dialysed. Dose as in GFR<10
mL/min.
D
HD Probably dialysed. Dose as in GFR<10
mL/min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/
min.
CAV/VVHD Dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function. Use with caution.
- **GFR 10–20**: Dose as in normal renal function. Use with caution.
- **GFR <10**: Dose as in normal renal function. Use with caution. APD/CAPD Possibly dialysed. Dose as in GFR<10 mL/min. D HD Probably dialysed. Dose as in GFR<10 mL/min. HDF/High flux Dialysed. Dose as in GFR<10 mL/ min. CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Rate of administration 1 hour 20–50 Dose as in normal renal function. Use Comments with caution. After reconstitution dilute to 0.15–1 mg/mL with 10–20 Dose as in normal renal function. Use sodium chloride 0.9%, glucose 5%. with caution. <10 Dose as in normal renal function. Use Other information with caution. • Manufacturer has not done any studies in renal failure but because of low renal clearance use doses as for normal renal function. Reference: 1. Mistry B, Gibiansky L, Hussein Z. Pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). J Clin Oncol. 29: 2011 (suppl; abstr 6551)....

---
## Acebutolol 7 (Page 26)
### 1. Database (Raw Text)
```text
GFR (mL/min)
• Hypertension
• Angina
• Arrhythmias
```
### 2. App Table View (Parsed)
- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Dialysed. Dose as in GFR<10 mL/ min.
- **HDF/High flux**: Dialysed. Dose as in GFR<10 mL/ min.
- **CAV/VVHD**: Dialysed. Dose as in GFR=10–25 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Beta-adrenoceptor blocker: 25–50 50% of normal dose, but frequency • Hypertension should not exceed once daily. • Angina 10–25 50% of normal dose, but frequency • Arrhythmias should not exceed once daily. <10 25–50% of normal dose, but frequency Dose in normal renal function should not exceed once daily. • Hypertension: 400 mg once a day or 200 mg twice a Dose in patients undergoing renal day, increased after 2 weeks to 400 mg twice daily if replacement therapies necessary • Angina: 400 mg once a day, or 200 mg twice daily APD/CAPD Unknown dialysability. Dose as in initially. Increase up to 300 mg 3 times daily; GFR<10 mL/min. maximum 1200 mg HD Dialysed. Dose as in GFR<10 mL/ • Arrhythmias: 400–1200 mg/day (in 2–3 divided min. doses) HDF/High flux Dia...

---
## Minoxidil (Page 681)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Start with small doses and titrate
according to response. See ‘Other
information’.
10–20 Start with small doses and titrate
according to response. See ‘Other
information’.
<10 Start with small doses and titrate
according to response. See ‘Other
information’.
APD/CAPD Dialysed. Dose as in GFR<10 mL/
min.
HD Dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/
min.
CAV/VVHD Dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Start with small doses and titrate according to response. See ‘Other information’.
- **GFR 10–20**: Start with small doses and titrate according to response. See ‘Other information’.
- **GFR <10**: Start with small doses and titrate according to response. See ‘Other information’. APD/CAPD Dialysed. Dose as in GFR<10 mL/ min. HD Dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Dialysed. Dose as in GFR<10 mL/ min. CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) as renal function worsened. Substantial accumulation 20–50 Start with small doses and titrate of minoxidil might occur in these patients during according to response. See ‘Other multiple-dose therapy. Recommended that minoxidil therapy be initiated with smaller doses or a longer information’. dose interval in patients with significant renal 10–20 Start with small doses and titrate impairment. according to response. See ‘Other • Minoxidil is a peripheral vasodilator and should be information’. given in conjunction with a diuretic to control salt <10 Start with small doses and titrate and water retention, and a beta-blocker to control according to response. See ‘Other reflex tachycardia. Patients on dialysis do not need to information’. be given minoxidi...

---
## Fesoterodine fumarate 425 (Page 444)
### 1. Database (Raw Text)
```text
GFR (mL/min)
50–80 Dose as in normal renal function.
30–50 Dose as in normal renal function. See
'Other information'.
<30 4 mg daily. See 'Other information'.
```
### 2. App Table View (Parsed)
- **GFR 50–80**: Dose as in normal renal function.
- **GFR 30–50**: Dose as in normal renal function. See 'Other information'.
- **GFR <30**: 4 mg daily. See 'Other information'.
- **APD/CAPD**: Probably dialysed. Dose as in GFR<30 mL/min.
- **HD**: Probably dialysed. Dose as in GFR<30 mL/min.
- **HDF/High flux**: Probably dialysed. Dose as in GFR<30 mL/min.
- **CAV/VVHD**: Probably dialysed. Dose as in GFR=30–50 mL/min. • Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide. • Antifungals: dose reduction advised with itraconazole and ketoconazole. • Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir. • Induction of CYP3A4 may lead to subtherapeutic F plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not recommended. • Co-

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • UK licensed product information for fesoterodine fumarate states that patients with GFR=30–80 mL/ 50–80 Dose as in normal renal function. min, should increase their dose with caution; those 30–50 Dose as in normal renal function. See also receiving moderate CYP3A4 inhibitors should 'Other information'. not exceed an oral dose of fesoterodine fumarate of <30 4 mg daily. See 'Other information'. 4 mg once daily, and concomitant potent CYP3A4 inhibitors are not recommended. Patients with Dose in patients undergoing renal GFR<30 mL/min and concomitant moderate or replacement therapies potent CYP3A4 inhibitors are advised not to take APD/CAPD Probably dialysed. Dose as in GFR<30 fesoterodine. mL/min. • In patients with GFR=30–80 mL/min, C and max HD Proba...

---
## Stavudine (Page 959)
### 1. Database (Raw Text)
```text
GFR (mL/min)
26–50 <60 kg: 15 mg twice daily; >60 kg: 20
mg twice daily
S <25 <60 kg: 15 mg daily; >60 kg: 20 mg
daily
APD/CAPD Unknown dialysability. Dose as in
GFR<25 mL/min.
HD Dialysed. Dose as in GFR<25 mL/
min.
HDF/High flux Dialysed. Dose as in GFR<25 mL/
min.
CAV/VVHD Dialysed. Dose as in GFR=26–50
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 26–50**: <60 kg: 15 mg twice daily; >60 kg: 20 mg twice daily S <25 <60 kg: 15 mg daily; >60 kg: 20 mg daily APD/CAPD Unknown dialysability. Dose as in GFR<25 mL/min. HD Dialysed. Dose as in GFR<25 mL/ min. HDF/High flux Dialysed. Dose as in GFR<25 mL/ min. CAV/VVHD Dialysed. Dose as in GFR=26–50 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Administer at least an hour before food. 26–50 <60 kg: 15 mg twice daily; >60 kg: 20 mg twice daily Other information S <25 <60 kg: 15 mg daily; >60 kg: 20 mg • Oral bioavailability is 86%. daily • Clearance by haemodialysis is 120 mL/min. • Lactic acidosis, sometimes fatal, has been reported with the use of nucleoside analogues. • Patients with ESRF are more likely to develop peripheral neuropathy....

---
## Thiotepa (Page 1013)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 IM: Use a reduced dose with caution.
10–20 IM: Use a reduced dose with caution.
<10 IM: Use a reduced dose with caution.
T
APD/CAPD Unknown dialysability. Dose as in
GFR<10 mL/min.
HD Dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Dialysed. Dose as in GFR<10 mL/
min.
CAV/VVHD Dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: IM: Use a reduced dose with caution.
- **GFR 10–20**: IM: Use a reduced dose with caution.
- **GFR <10**: IM: Use a reduced dose with caution. T APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min. HD Dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Dialysed. Dose as in GFR<10 mL/ min. CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) chloride 0.9% (1000 mL if dose >500 mg) 20–50 IM: Use a reduced dose with caution. 10–20 IM: Use a reduced dose with caution. Other information <10 IM: Use a reduced dose with caution. • Manufacturer advises to use with caution due to lack of pharmacokinetic studies in renal impairment. • Haemorrhagic cystitis has been reported. T...

---
## Riociguat 883 (Page 902)
### 1. Database (Raw Text)
```text
GFR (mL/min)
30–50 Dose as in normal renal function. See
'Other information'.
15–30 Dose as in normal renal function. See
'Other information'.
<15 Use with caution. See 'Other
information'.
APD/CAPD Unlikely to be dialysed. Dose as in
GFR<15 mL/min.
HD Unlikely to be dialysed. Dose as in
GFR<15 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in
GFR<15 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in
GFR=15–30 mL/min.
```
### 2. App Table View (Parsed)
- **GFR 30–50**: Dose as in normal renal function. See 'Other information'.
- **GFR 15–30**: Dose as in normal renal function. See 'Other information'.
- **GFR <15**: Use with caution. See 'Other information'. APD/CAPD Unlikely to be dialysed. Dose as in GFR<15 mL/min. HD Unlikely to be dialysed. Dose as in GFR<15 mL/min. HDF/High flux Unlikely to be dialysed. Dose as in GFR<15 mL/min. CAV/VVHD Unlikely to be dialysed. Dose as in GFR=15–30 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) dose re-titration is required. R • UK manufacturer does not recommend use in 30–50 Dose as in normal renal function. See patients with CRCL<30 mL/min due to lack of 'Other information'. studies. US data sheet use with caution due to lack of 15–30 Dose as in normal renal function. See data with a CRCL<15 mL/min. 'Other information'. • Patients with renal impairment are more at risk <15 Use with caution. See 'Other of hypotension due to increased exposure so dose information'. should be titrated carefully. • In non-smoking individuals with CRCL= 80–50 mL/min, 50–30 mL/min or <30 mL/min, riociguat plasma concentrations (AUC) were increased by 53%, 139% or 54%, respectively. • Oral bioavailability is 94%....

---
## Enoxaparin sodium (LMWH) 367 (Page 386)
### 1. Database (Raw Text)
```text
GFR (mL/min)
30–80 Dose as in normal renal function.
15–30 Prophylaxis: 20 mg daily. Treatment: 1
mg/kg daily. Initial stat dose of 30 mg
for patients who have had a STEMI
and are <75 years.
<15 Treatment: 1 mg/kg daily. Initial stat
dose of 30 mg for patients who have
had a STEMI and are <75 years.
Prophylaxis: 20 mg daily. See 'Other
information'.
APD/CAPD Not dialysed. Dose as in GFR<15 mL/
min.
HD Not dialysed. Dose as in GFR<15 mL/
min.
HDF/High flux Dialysed. Dose as in GFR<15 mL/ E
min.
CAV/VVHD Not dialysed. Dose as in GFR=15–30
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 30–80**: Dose as in normal renal function.
- **GFR 15–30**: Prophylaxis: 20 mg daily. Treatment: 1 mg/kg daily. Initial stat dose of 30 mg for patients who have had a STEMI and are <75 years.
- **GFR <15**: Treatment: 1 mg/kg daily. Initial stat dose of 30 mg for patients who have had a STEMI and are <75 years. Prophylaxis: 20 mg daily. See 'Other information'. APD/CAPD Not dialysed. Dose as in GFR<15 mL/ min. HD Not dialysed. Dose as in GFR<15 mL/ min. HDF/High flux Dialysed. Dose as in GFR<15 mL/ E min. CAV/VVHD Not dialysed. Dose as in GFR=15–30 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • From December 2016, the manufacturer has changed 30–80 Dose as in normal renal function. the dosing in severe renal impairment in line with 15–30 Prophylaxis: 20 mg daily. Treatment: 1 European guidelines. It is now contraindicated for all mg/kg daily. Initial stat dose of 30 mg indications in severe renal impairment apart from its for patients who have had a STEMI use for dialysis anti-coagulation. and are <75 years. • A linear relationship between anti-Xa plasma <15 Treatment: 1 mg/kg daily. Initial stat clearance and creatinine clearance at steady-state has dose of 30 mg for patients who have been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal had a STEMI and are <75 years. function. In patients w...

---
## Rivastigmine (Page 911)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Start at a low dose and gradually
increase.
R 10–20 Start at a low dose and gradually
increase.
<10 Start at a low dose and gradually
increase.
APD/CAPD Likely dialysability. Dose as in
GFR<10 mL/min.
HD Likely dialysability. Dose as in
GFR<10 mL/min.
HDF/High flux Likely dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Likely dialysability. Dose as in
GFR=10–20 mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Start at a low dose and gradually increase. R 10–20 Start at a low dose and gradually increase.
- **GFR <10**: Start at a low dose and gradually increase. APD/CAPD Likely dialysability. Dose as in GFR<10 mL/min. HD Likely dialysability. Dose as in GFR<10 mL/min. HDF/High flux Likely dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Likely dialysability. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) 20–50 Start at a low dose and gradually increase. R 10–20 Start at a low dose and gradually increase. <10 Start at a low dose and gradually increase....

---
## Trifluoperazine (Page 1053)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function. Start
with low dose.
10–20 Dose as in normal renal function. Start
with low dose.
<10 Dose as in normal renal function. Start
with low dose.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function. Start with low dose.
- **GFR 10–20**: Dose as in normal renal function. Start with low dose.
- **GFR <10**: Dose as in normal renal function. Start with low dose.
- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/ min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/ min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Atomoxetine: increased risk of ventricular arrhythmias. 20–50 Dose as in normal renal function. Start • Beta-blockers: enhanced hypotensive effect; with low dose. increased risk of ventricular arrhythmias with sotalol. 10–20 Dose as in normal renal function. Start • Cytotoxics: increased risk of ventricular arrhythmias with low dose. with arsenic trioxide. <10 Dose as in normal renal function. Start • Diuretics: enhanced hypotensive effect. with low dose. • Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity. Dose in patients undergoing renal • Pentamidine: increased risk of ventricular arrhythmias. replacement therapies T APD/CAPD Not dialysed. Dose as in GFR<10 mL/ Administration min. Reconstitution HD Not dialysed. Do...

---
## Exenatide 409 (Page 428)
### 1. Database (Raw Text)
```text
GFR (mL/min)
30–50 Increase dose to 10 mcg with caution.
Avoid MR.
10–30 Avoid. See ‘Other information’.
<10 Avoid. See ‘Other information’.
```
### 2. App Table View (Parsed)
- **GFR 30–50**: Increase dose to 10 mcg with caution. Avoid MR.
- **GFR 10–30**: Avoid. See ‘Other information’.
- **GFR <10**: Avoid. See ‘Other information’.
- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–30 mL/min. • Anticoagulants: possibly enhances anticoagulant effect of warfarin. • Other nephrotoxins: avoid concomitant use. E

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • May cause renal failure including proteinuria. Avoid in patients with pre-existing renal impairment. 30–50 Increase dose to 10 mcg with caution. Reference: Avoid MR. 1. Linnebjerg H, Kothare PA, Park S, et al. Effect 10–30 Avoid. See ‘Other information’. of renal impairment on the pharmacokinetics of <10 Avoid. See ‘Other information’. exenatide. Br J Clin Pharmacol. 2007; 64(3): 317–27. Dose in patients undergoing renal replacement therapies APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min. HD Unknown dialysability. Dose as in GFR<10 mL/min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in GFR=10–30 mL/min....

---
## Zolpidem tartrate 1085 (Page 1104)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Not dialysed. Dose as in normal renal
function.
HD Not dialysed. Dose as in normal renal
function.
HDF/High flux Unknown dialysability. Dose as in
normal renal function.
CAV/VVHD Not dialysed. Dose as in normal renal
function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Not dialysed. Dose as in normal renal function. HD Not dialysed. Dose as in normal renal function. HDF/High flux Unknown dialysability. Dose as in normal renal function. CAV/VVHD Not dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Oral 20–50 Dose as in normal renal function. Rate of administration 10–20 Dose as in normal renal function. — <10 Dose as in normal renal function. Other information • First pass metabolism by liver is 35%. • Clearance is reduced in renal impairment. • Oral bioavailability is 70%. Z...

---
## Oxytetracycline (Page 775)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 250 mg 4 times a day.
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Unknown dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: 250 mg 4 times a day. APD/CAPD Not dialysed. Dose as in GFR<10 mL/ min. HD Not dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Rate of administration 20–50 Dose as in normal renal function. — 10–20 Dose as in normal renal function. <10 250 mg 4 times a day. Other information • Avoid if possible in renal impairment, due to potential nephrotoxicity and increased risk of azotaemia, hyperphosphataemia and acidosis. • May cause an increase in blood urea which is dose related. • Avoid in SLE....

---
## Lercanidipine hydrochloride (Page 597)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Use small doses and titrate to response.
10–20 Use small doses and titrate to response.
<10 Use small doses and titrate to response.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Use small doses and titrate to response.
- **GFR 10–20**: Use small doses and titrate to response.
- **GFR <10**: Use small doses and titrate to response.
- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min. • Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration. • Anaesthetics: enhanced hypotensive effect. • Antibacterials: metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin – avoid with erythromycin. • Antidepressants: enhanced hypotensive effect with MAOIs. • Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone. • Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole – avoid; negative inotropic effect possibly increased with itraconazole. • Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post- synaptic alpha-blockers. • Antivirals: concentration increased by ritonavir – avoid. • Cardiac glycosides: digoxin concentration increased. • Ciclosporin: concentration of both drugs may be increased – avoid. • Grapefruit juice: concentration increased – avoid.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Administration 20–50 Use small doses and titrate to response. Reconstitution 10–20 Use small doses and titrate to response. — <10 Use small doses and titrate to response. Route Oral Dose in patients undergoing renal Rate of administration replacement therapies — APD/CAPD Unlikely to be dialysed. Dose as in Comments GFR<10 mL/min. Take before food. HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. Other information HDF/High flux Unknown dialysability. Dose as in • Causes less peripheral oedema than other calcium- GFR<10 mL/min. channel blockers. CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min....

---
## Hydrocortisone sodium succinate 495 (Page 514)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HD**: Unlikely to be dialysed. Dose as in normal renal function.
- **HDF/High flux**: Unlikely to be dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in normal renal function. • Aldesleukin: avoid concomitant use. • Antibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced. • Anticoagulants: efficacy of coumarins and phenindione may be altered. • Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone. • Antifungals: increased risk of hypokalaemia with amphotericin – avoid; metabolism possibly inhibited H by itraconazole and ketoconazole. • Antivirals: concentration possibly increased by ritonavir. • Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids. • Cobicistat: concentration of hydrocortisone possibly increased – increased risk of adrenal suppression. • Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics. • Vaccines: high dose corticosteroids can impair immune response to vaccines – avoid concomitant use with live vaccines.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Route 20–50 Dose as in normal renal function. IV injection, IV infusion, IM 10–20 Dose as in normal renal function. Rate of administration <10 Dose as in normal renal function. IV bolus: 2–3 minutes Comments Dose in patients undergoing renal Minimum volume 100 mg in 50 mL. (UK Critical Care replacement therapies Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006). APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. Other information HD Unlikely to be dialysed. Dose as in normal renal function. • Non-plasma protein bound hydrocortisone is HDF/High flux Unlikely to be dialysed. Dose as in removed by HD. normal renal function. • One study has shown that plasma clearance rates of CAV/VVHD Unlikel...

---
## Glimepiride 483 (Page 502)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Initially 1 mg and monitor closely.
<10 Initially 1 mg and monitor closely.
APD/CAPD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in
GFR=10–20 mL/min.
G
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Initially 1 mg and monitor closely.
- **GFR <10**: Initially 1 mg and monitor closely. APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min. CAV/VVHD Unlikely to be dialysed. Dose as in GFR=10–20 mL/min. G

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Reconstitution — 20–50 Dose as in normal renal function. 10–20 Initially 1 mg and monitor closely. Route <10 Initially 1 mg and monitor closely. Oral Rate of administration — Other information • Contraindicated by manufacturer in UK, dosage in severe renal impairment is from US data sheet....

---
## Calcitriol (Page 175)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
Titrate to response.
10–20 Dose as in normal renal function.
Titrate to response.
<10 Dose as in normal renal function.
Titrate to response.
APD/CAPD Unlikely to be dialysed. Dose as in
normal renal function.
HD Not dialysed. Dose as in normal renal
function.
HDF/High flux Not dialysed. Dose as in normal renal
function.
CAV/VVHD Unknown dialysability. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function. Titrate to response.
- **GFR 10–20**: Dose as in normal renal function. Titrate to response.
- **GFR <10**: Dose as in normal renal function. Titrate to response. APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. HD Not dialysed. Dose as in normal renal function. HDF/High flux Not dialysed. Dose as in normal renal function. CAV/VVHD Unknown dialysability. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) may be affected. 20–50 Dose as in normal renal function. • Hypercalcaemia and hypercalciuria are the major Titrate to response. side effects, and indicate excessive dosage. 10–20 Dose as in normal renal function. Titrate to response. <10 Dose as in normal renal function. Titrate to response....

---
## Mitotane (Page 687)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Use with caution and monitor levels.
10–20 Use with caution and monitor levels.
<10 Avoid. See 'Other information'.
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/
min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Use with caution and monitor levels.
- **GFR 10–20**: Use with caution and monitor levels.
- **GFR <10**: Avoid. See 'Other information'. APD/CAPD Not dialysed. Dose as in GFR<10 mL/ min. HD Not dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Not dialysed. Dose as in GFR<10 mL/ min. CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Other information 20–50 Use with caution and monitor levels. 10–20 Use with caution and monitor levels. • Aim for plasma mitotane levels of 14–20 mg/L. <10 Avoid. See 'Other information'. • There is no experience of mitotane in patients with renal failure so manufacturer is unable to advise on dosing. • No reduction for renal failure in US data sheet....

---
## Levetiracetam (Page 601)
### 1. Database (Raw Text)
```text
GFR (mL/min)
50–79 500–1000 mg twice daily
30–49 250–750 mg twice daily
<30 250–500 mg twice daily
APD/CAPD Likely to be dialysed. 750 mg loading
dose then 500–1000 mg daily.
HD Dialysed. 750 mg loading dose then
500–1000 mg once daily.
HDF/High flux Dialysed. 750 mg loading dose then
500–1000 mg once daily.
CAV/VVHD Likely to be dialysed. Dose as in
GFR=30–49 mL/min.
```
### 2. App Table View (Parsed)
- **GFR 50–79**: 500–1000 mg twice daily
- **GFR 30–49**: 250–750 mg twice daily
- **GFR <30**: 250–500 mg twice daily APD/CAPD Likely to be dialysed. 750 mg loading dose then 500–1000 mg daily. HD Dialysed. 750 mg loading dose then 500–1000 mg once daily. HDF/High flux Dialysed. 750 mg loading dose then 500–1000 mg once daily. CAV/VVHD Likely to be dialysed. Dose as in GFR=30–49 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) 50–79 500–1000 mg twice daily 30–49 250–750 mg twice daily <30 250–500 mg twice daily...

---
## Maraviroc (Page 635)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–80 If administered without potent
CYP3A4 inhibitors dose as in normal
renal function.
If administered with potent CYP3A4
inhibitors: 150 mg daily.
10–20 If administered without potent
CYP3A4 inhibitors dose as in normal
renal function.
If administered with potent CYP3A4
inhibitors: 150 mg daily.
<10 If administered without potent
CYP3A4 inhibitors dose as in normal
renal function.
If administered with potent CYP3A4
inhibitors: 150 mg daily.
APD/CAPD Unknown dialysability. Dose as in
GFR<10 mL/min.
HD Some dialysability. Dose as in GFR<10
mL/min.
HDF/High flux Probably dialysed. Dose as in GFR<10
mL/min.
CAV/VVHD Some dialysability. Dose as in
GFR=10–20 mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–80**: If administered without potent CYP3A4 inhibitors dose as in normal renal function. If administered with potent CYP3A4 inhibitors: 150 mg daily.
- **GFR 10–20**: If administered without potent CYP3A4 inhibitors dose as in normal renal function. If administered with potent CYP3A4 inhibitors: 150 mg daily.
- **GFR <10**: If administered without potent CYP3A4 inhibitors dose as in normal renal function. If administered with potent CYP3A4 inhibitors: 150 mg daily. APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min. HD Some dialysability. Dose as in GFR<10 mL/min. HDF/High flux Probably dialysed. Dose as in GFR<10 mL/min. CAV/VVHD Some dialysability. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) fosamprenavir reduced – avoid. 20–80 If administered without potent • Orlistat: absorption possibly reduced by orlistat. CYP3A4 inhibitors dose as in normal renal function. Administration If administered with potent CYP3A4 Reconstitution inhibitors: 150 mg daily. — 10–20 If administered without potent CYP3A4 inhibitors dose as in normal Route renal function. Oral If administered with potent CYP3A4 Rate of administration inhibitors: 150 mg daily. — <10 If administered without potent CYP3A4 inhibitors dose as in normal Other information renal function. • Increased risk of postural hypotension in renal If administered with potent CYP3A4 impairment especially if co-administered with potent inhibitors: 150 mg daily. CYP3A4 inhibitors. • Bioavailability is 2...

---
## Interferon alfa-2B 531 (Page 550)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
Monitor renal function closely.
10–20 Dose as in normal renal function.
Monitor renal function closely.
<10 Use with great caution. See ‘Other
information’.
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Not dialysed. Dose as in GFR<10 mL/
min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function. Monitor renal function closely.
- **GFR 10–20**: Dose as in normal renal function. Monitor renal function closely.
- **GFR <10**: Use with great caution. See ‘Other information’. APD/CAPD Not dialysed. Dose as in GFR<10 mL/ min. HD Not dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Not dialysed. Dose as in GFR<10 mL/ min. CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) rejection, acute renal failure and graft loss after interferon therapy. Hence extreme care should 20–50 Dose as in normal renal function. be exercised in the use of interferon after renal Monitor renal function closely. transplantation. 10–20 Dose as in normal renal function. • In patients undergoing haemodialysis, the interferon Monitor renal function closely. molecule may accumulate as it is too large to be <10 Use with great caution. See ‘Other dialysed and will not undergo renal degradation. information’. Hence, the dose may need to be adjusted....

---
## Morphine (Page 695)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 75% of normal dose
10–20 Use small doses (50% of dose),
e.g. 2.5–5 mg and extended dosing
intervals. Titrate according to response.
<10 Use small doses (25% of dose), e.g.
1.25–2.5 mg and extended dosing
intervals. Titrate according to response.
APD/CAPD Not dialysed. Dose as in GFR<10 mL/
min.
HD Dialysed – active metabolite removed
significantly. Dose as in GFR<10 mL/
min.
HDF/High flux Dialysed – active metabolite removed
significantly. Dose as in GFR<10 mL/
min.
CAV/VVHD Dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: 75% of normal dose
- **GFR 10–20**: Use small doses (50% of dose), e.g. 2.5–5 mg and extended dosing intervals. Titrate according to response.
- **GFR <10**: Use small doses (25% of dose), e.g. 1.25–2.5 mg and extended dosing intervals. Titrate according to response. APD/CAPD Not dialysed. Dose as in GFR<10 mL/ min. HD Dialysed – active metabolite removed significantly. Dose as in GFR<10 mL/ min. HDF/High flux Dialysed – active metabolite removed significantly. Dose as in GFR<10 mL/ min. CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Reconstitution 20–50 75% of normal dose — 10–20 Use small doses (50% of dose), Route e.g. 2.5–5 mg and extended dosing Oral, SC, IM, IV, PR intervals. Titrate according to response. Rate of administration <10 Use small doses (25% of dose), e.g. 2 mg/min (titrate according to response). 1.25–2.5 mg and extended dosing intervals. Titrate according to response. Other information • Doses in renal impairment are from Drug Prescribing in Renal Failure, 5th edition by Aronoff et al....

---
## Metoclopramide hydrochloride (Page 667)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Not dialysed. Dose as in normal renal
function.
HD Dialysed. Dose as in normal renal
function.
HDF/High flux Dialysed. Dose as in normal renal
function.
CAV/VVHD Dialysed. Dose as in normal renal
function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Not dialysed. Dose as in normal renal function. HD Dialysed. Dose as in normal renal function. HDF/High flux Dialysed. Dose as in normal renal function. CAV/VVHD Dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Other information 20–50 Dose as in normal renal function. • Increased risk of extrapyramidal reactions in severe 10–20 Dose as in normal renal function. renal impairment. <10 Dose as in normal renal function. • Can be used for hiccups at a dose of 10 mg 3 times a day....

---
## Chloral hydrate 197 (Page 216)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 1 tablet at night.
<10 Avoid.
C
APD/CAPD Unknown dialysability. Avoid.
HD Dialysed. Avoid.
HDF/High flux Dialysed. Avoid.
CAV/VVHD Dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: 1 tablet at night.
- **GFR <10**: Avoid. C APD/CAPD Unknown dialysability. Avoid. HD Dialysed. Avoid. HDF/High flux Dialysed. Avoid. CAV/VVHD Dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Comments 20–50 Dose as in normal renal function. Take with water (or milk) 15–30 minutes before bedtime. 10–20 1 tablet at night. <10 Avoid. Other information • Manufacturer advises to avoid in patients with marked hepatic or renal impairment, severe cardiac disease, marked gastritis and those susceptible to acute attacks of porphyria. • Chloral hydrate followed by intravenous furosemide may result in sweating, hot flushes, and variable blood pressure including hypertension....

---
## Ceftazidime 183 (Page 202)
### 1. Database (Raw Text)
```text
GFR (mL/min)
31–50 1–2 g every 12 hours.
16–30 1–2 g every 24 hours.
6–15 500 mg – 1 g every 24 hours.
<5 500 mg – 1 g every 48 hours.
```
### 2. App Table View (Parsed)
- **GFR 31–50**: 1–2 g every 12 hours.
- **GFR 16–30**: 1–2 g every 24 hours.
- **GFR 6–15**: 500 mg – 1 g every 24 hours.
- **GFR <5**: 500 mg – 1 g every 48 hours.
- **APD/CAPD**: Dialysed. 500 mg – 1 g every 24 hours.
- **HD**: Dialysed. 500 mg – 1 g every 48 hours or post dialysis.
- **HDF/High flux**: Dialysed. 500 mg – 2 g every 48 hours or post dialysis.
- **CAV/VVHD**: Dialysed. 2 g every 8 hours1 or 1–2 g every 12 hours.1,2 CVVHD/HDF Dialysed. 2 g every 12 hours.2 See ‘Other information’.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) haemodialysis may be given a dose of 2 g, 3 times a week post HD. 31–50 1–2 g every 12 hours. • There are several methods of dosing drugs while a 16–30 1–2 g every 24 hours. patient is undergoing continuous renal replacement 6–15 500 mg – 1 g every 24 hours. therapy (CRRT) including the following guideline: <5 500 mg – 1 g every 48 hours. The patient’s GFR is equated to the total fluid ‘flux’ within the filter circuit by adding up all the fluid Dose in patients undergoing renal going through the filter circuit i.e. blood flow, citrate, replacement therapies dialysate fluid and replacement fluid and dividing it by 60, which gives a value in mL /minute, equated to APD/CAPD Dialysed. 500 mg – 1 g every 24 hours. a patient GFR. E.g. blood flow rate = 100 m...

---
## Folic acid (Page 471)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Dialysed. Dose as in normal renal
function.
HD Dialysed. Dose as in normal renal
function.
HDF/High flux Dialysed. Dose as in normal renal
function.
CAV/VVHD Dialysed. Dose as in normal renal
function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Dialysed. Dose as in normal renal function. HD Dialysed. Dose as in normal renal function. HDF/High flux Dialysed. Dose as in normal renal function. CAV/VVHD Dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) month, then 5 mg/day. • Doses up to 15 mg daily have been used in cases of 20–50 Dose as in normal renal function. malabsorption. 10–20 Dose as in normal renal function. • Most nutritionists recommend 0.5–1 mg folic acid <10 Dose as in normal renal function. daily for patients on HD or CAPD; may accumulate in uraemic patients. • Dosage used by dialysis units varies from 5 mg daily to 5 mg once weekly....

---
## Fosphenytoin sodium (Page 483)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Reduce dose or rate by 10–25% and
monitor carefully (except for status
epilepticus).
10–20 Reduce dose or rate by 10–25% and
monitor carefully (except for status
epilepticus).
<10 Reduce dose or rate by 10–25% and
monitor carefully (except for status
epilepticus).
APD/CAPD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HD Not dialysed. Dose as in GFR<10 mL/
min.
HDF/High flux Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
CAV/VVHD Not dialysed. Dose as in GFR=10–20
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus).
- **GFR 10–20**: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus).
- **GFR <10**: Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus). APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HD Not dialysed. Dose as in GFR<10 mL/ min. HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min. CAV/VVHD Not dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) tricyclics reduced; concentration reduced by St John’s 20–50 Reduce dose or rate by 10–25% and wort – avoid. monitor carefully (except for status • Antiepileptics: concentration of both drugs reduced epilepticus). with carbamazepine, concentration may also be 10–20 Reduce dose or rate by 10–25% and increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stripentol and monitor carefully (except for status topiramate; concentration of ethosuximide, active epilepticus). oxcarbazepine metabolite, retigabine, rufinamide <10 Reduce dose or rate by 10–25% and (concentration of phenytoin possibly increased), monitor carefully (except for status topiramate and valproate possibly reduced; epilepticus). concentration of eslicarbazepine, ethosuxi...

---
## Degarelix (Page 317)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use
with caution.
APD/CAPD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. Use with caution. APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min. CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Other information 20–50 Dose as in normal renal function. • Use with caution in severe renal impairment due to lack of experience. 10–20 Dose as in normal renal function. <10 Dose as in normal renal function. Use • May prolong QT interval. with caution. • Degarelix is injected to form a subcutaneous depot, and the pharmacokinetics of the drug is strongly influenced by the concentration of the injected solution. • A phase III study has demonstrated that the clearance of degarelix in patients with mild to moderate renal impairment is reduced by approximately 23% so no dose adjustment is required....

---
## Reteplase 873 (Page 892)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use
with caution.
APD/CAPD Unknown dialysability. Dose as in
GFR<10 mL/min.
HD Unknown dialysability. Dose as in
GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. Use with caution. APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min. HD Unknown dialysability. Dose as in GFR<10 mL/min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Do not mix with heparin in the same line. 20–50 Dose as in normal renal function. Other information 10–20 Dose as in normal renal function. <10 Dose as in normal renal function. Use • Heparin and aspirin should be given before and after with caution. reteplase therapy to reduce the risk of re-thrombosis but may increase the risk of bleeding. R • Half-life is increased in severe renal failure in animal models. • Possible increased risk of bleeding complications in severe renal impairment. • Contraindicated in severe renal impairment in UK SPC but only use with caution in US data sheet due to increased risk of bleeding....

---
## Pentostatin 785 (Page 804)
### 1. Database (Raw Text)
```text
GFR (mL/min)
50–60 50% of dose. See ‘Other information’.
10–50 See ‘Other information’
<10 See ‘Other information’
```
### 2. App Table View (Parsed)
- **GFR 50–60**: 50% of dose. See ‘Other information’.
- **GFR 10–50**: See ‘Other information’
- **GFR <10**: See ‘Other information’
- **APD/CAPD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HD**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Likely dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–50 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002; 50(2): 121–6.) 50–60 50% of dose. See ‘Other information’. • Another study used it in a haemodialysis patient at 10–50 See ‘Other information’ increasing doses of 1, 2, then 3 mg/m2. Treatment <10 See ‘Other information’ was then continued at a dose of 2 mg/m2. The patient was dialysed for 4 hours 1–2 hours after Dose in patients undergoing renal receiving the pentostatin to remove any remaining replacement therapies drug. The main complication was anorexia. Tumour P APD/CAPD Unknown dialysability. Dose as in lysis syndrome also occurred 4 days after the 3 GFR<10 mL/min. mg/m2 dose. (Arima N, Sugiyama T. Pentostatin treatment for a patient with chronic type adult HD Unknown dialy...

---
## Etodolac 397 (Page 416)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function, but
avoid if possible.
10–20 Dose as in normal renal function, but
avoid if possible.
<10 Dose as in normal renal function, but
only use if on dialysis.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function, but avoid if possible.
- **GFR 10–20**: Dose as in normal renal function, but avoid if possible.
- **GFR <10**: Dose as in normal renal function, but only use if on dialysis.
- **APD/CAPD**: Not dialysed. Dose as in normal renal function. See 'Other information'.
- **HD**: Not dialysed. Dose as in normal renal function. See 'Other information'.
- **HDF/High flux**: Unknown dialysability. Dose as in normal renal function. See 'Other information'.
- **CAV/VVHD**: Unlikely to be dialysed. Use lowest possible dose.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with 20–50 Dose as in normal renal function, but potassium-sparing diuretics. avoid if possible. • Lithium: excretion decreased. 10–20 Dose as in normal renal function, but • Pentoxifylline: increased risk of bleeding. avoid if possible. • Tacrolimus: increased risk of nephrotoxicity. <10 Dose as in normal renal function, but only use if on dialysis. Administration Dose in patients undergoing renal Reconstitution replacement therapies — Route APD/CAPD Not dialysed. Dose as in normal renal Oral function. See 'Other information'. Rate of administration HD Not dialysed. Dose as in normal renal — function. See 'Other information'. HDF/High flux Unknown dialysability...

---
## Belatacept 113 (Page 132)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Not dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function. • Vaccines: avoid concomitant use with live vaccines.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • MPA exposure is approximately 40% higher with 20–50 Dose as in normal renal function. belatacept co-administration than with ciclosporin 10–20 Dose as in normal renal function. co-administration. <10 Dose as in normal renal function. • There was a trend toward higher clearance of belatacept with increasing body weight. Dose in patients undergoing renal replacement therapies APD/CAPD Not dialysed. Dose as in normal renal function. HD Not dialysed. Dose as in normal renal function. HDF/High flux Not dialysed. Dose as in normal renal function. CAV/VVHD Not dialysed. Dose as in normal renal function....

---
## Carmustine 173 (Page 192)
### 1. Database (Raw Text)
```text
GFR (mL/min)
45–60 Implant: Dose as in normal renal
function. IV: 80% of dose.1
30–45 Implant: Dose as in normal renal
function. IV: 75% of dose.1
<30 Implant: Dose as in normal renal
function. IV: Avoid.1
C
APD/CAPD Not dialysed. Dose as in GFR<30 mL/
min.
HD Not dialysed. Dose as in GFR<30 mL/
min. See 'Other information'.
HDF/High flux Unknown dialysability. Dose as
in GFR<30 mL/min. See 'Other
information'.
CAV/VVHD Not dialysed. Dose as in GFR=30–45
mL/min.
```
### 2. App Table View (Parsed)
- **GFR 45–60**: Implant: Dose as in normal renal function. IV: 80% of dose.1
- **GFR 30–45**: Implant: Dose as in normal renal function. IV: 75% of dose.1
- **GFR <30**: Implant: Dose as in normal renal function. IV: Avoid.1 C APD/CAPD Not dialysed. Dose as in GFR<30 mL/ min. HD Not dialysed. Dose as in GFR<30 mL/ min. See 'Other information'. HDF/High flux Unknown dialysability. Dose as in GFR<30 mL/min. See 'Other information'. CAV/VVHD Not dialysed. Dose as in GFR=30–45 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) 500 mL of sodium chloride 0.9% or glucose 5%. 45–60 Implant: Dose as in normal renal Other information function. IV: 80% of dose.1 30–45 Implant: Dose as in normal renal • Renal abnormalities, e.g. a decrease in kidney size: function. IV: 75% of dose.1 progressive azotaemia and renal failure have been <30 Implant: Dose as in normal renal reported in patients receiving large cumulative doses function. IV: Avoid.1 after prolonged therapy. • Carmustine has been used at normal dose in a haemodialysis patient without any problems.2 References: 1. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21: 33–64. 2. Boesler B, Czock D, Keller F, et al. Clinical course of haemo...

---
## Colestipol hydrochloride 253 (Page 272)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Not dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function. C • Anticoagulants: may enhance or reduce effects of coumarins and phenindione. • Ciclosporin: no reports of an interaction; however, ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may interfere with ciclosporin absorption.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible 20–50 Dose as in normal renal function. interference with absorption. 10–20 Dose as in normal renal function. • Colestipol granules may be administered as a <10 Dose as in normal renal function. suspension in water or a flavoured vehicle. • Colestipol orange contains 32.5 mg aspartame (18.2 Dose in patients undergoing renal mg phenylalanine) per sachet. replacement therapies APD/CAPD Not dialysed. Dose as in normal renal Other information function. • Colestipol may interfere with the absorption of fat HD Not dialysed. Dose as in normal renal soluble vitamins. function. HDF/High flux Not dialysed. Dose as in normal renal function. CAV/VVHD Not dialysed....

---
## Fenofibrate 417 (Page 436)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–60 134 mg daily.
15–20 67 mg daily.
<15 Avoid.
```
### 2. App Table View (Parsed)
- **GFR 20–60**: 134 mg daily.
- **GFR 15–20**: 67 mg daily.
- **GFR <15**: Avoid.
- **APD/CAPD**: Unlikely to be dialysed. Avoid.
- **HD**: Not dialysed. Avoid.
- **HDF/High flux**: Unlikely to be dialysed. Avoid.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=15–20 mL/min. • Antibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant use. • Anticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INR. • Antidiabetics: may improve glucose tolerance F and have an additive effect with insulin or sulphonylureas. • Ciclosporin: ciclosporin levels appear to be unaffected; however, it is recommended that concomitant therapy should be avoided because of the possibility of elevated serum creatinine levels. • Colchicine: possible increased risk of myopathy. • Lipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe (maximum 20 mg of rosuvastatin); increased risk of cholelithiasis and gallbladder disease with ezetimibe – avoid with ezetimibe. Administration Reconstitution — Route Oral Rate of administration — Other information • A few studies have noted that use of second- generation fibrates in transplant recipients is hampered by frequent rises in serum creatinine. • Avoid use in patients with GFR<10 mL/min due to increased risk of rhabdomyolysis. • Contraindicated by some manufacturers if eGFR<30 mL/ min/1.73m2 and advise a dose of 67 mg once daily if eGFR= 30–59 mL/min/1.73m2.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Rate of administration 20–60 134 mg daily. — 15–20 67 mg daily. <15 Avoid. Other information • A few studies have noted that use of second- Dose in patients undergoing renal generation fibrates in transplant recipients is replacement therapies hampered by frequent rises in serum creatinine. APD/CAPD Unlikely to be dialysed. Avoid. • Avoid use in patients with GFR<10 mL/min due to HD Not dialysed. Avoid. increased risk of rhabdomyolysis. HDF/High flux Unlikely to be dialysed. Avoid. • Contraindicated by some manufacturers if eGFR<30 CAV/VVHD Unlikely to be dialysed. Dose as in mL/ min/1.73m2 and advise a dose of 67 mg once GFR=15–20 mL/min. daily if eGFR= 30–59 mL/min/1.73m2....

---
## Micafungin 655 (Page 674)
### 1. Database (Raw Text)
```text
GFR (mL/min)
• Treatment of invasive candidiasis
• Treatment of oesophageal candidiasis
• Prophylaxis of Candida infection in patients
undergoing allogeneic haematopoietic stem cell
transplantation or patients who are expected to have
neutropenia
```
### 2. App Table View (Parsed)
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Not dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Antimycotic: 20–50 Dose as in normal renal function. • Treatment of invasive candidiasis 10–20 Dose as in normal renal function. • Treatment of oesophageal candidiasis <10 Dose as in normal renal function. • Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell Dose in patients undergoing renal transplantation or patients who are expected to have replacement therapies neutropenia APD/CAPD Not dialysed. Dose as in normal renal function. Dose in normal renal function HD Not dialysed. Dose as in normal renal • Weight >40 kg: 50–200 mg once daily function. • Weight <40 kg: 1–4 mg/kg HDF/High flux Not dialysed. Dose as in normal renal • (Dose depends on indication) function. CAV/VVHD Not dialysed. Dose as in normal rena...

---
## Insulin – soluble (Actrapid or Humulin S) 529 (Page 548)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Variable.
10–20 Variable.
<10 Variable.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Variable.
- **GFR 10–20**: Variable.
- **GFR <10**: Variable.
- **APD/CAPD**: Not dialysed. Dose according to clinical response.
- **HD**: Not dialysed. Dose according to clinical response.
- **HDF/High flux**: Not dialysed. Dose according to clinical response.
- **CAV/VVHD**: Not dialysed. Dose according to clinical response.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Monitor blood glucose. • Prior to insulin / glucose infusion for hyperkalaemia, 20–50 Variable. give IV 20 mL 10% calcium gluconate to protect 10–20 Variable. myocardium and 50–100 mL 8.4% sodium <10 Variable. bicarbonate to correct acidosis. • Commence calcium resonium 15 g 4 times per day Dose in patients undergoing renal orally. replacement therapies • Insulin is metabolised renally; therefore, APD/CAPD Not dialysed. Dose according to clinical requirements may be reduced in ERF. response. HD Not dialysed. Dose according to clinical response. HDF/High flux Not dialysed. Dose according to clinical response. CAV/VVHD Not dialysed. Dose according to clinical response....

---
## Fentanyl 419 (Page 438)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 75% of normal dose. Titrate according
F
to response.
10–20 75% of normal dose. Titrate according
to response.
<10 50% of normal dose. Titrate according
to response.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: 75% of normal dose. Titrate according F to response.
- **GFR 10–20**: 75% of normal dose. Titrate according to response.
- **GFR <10**: 50% of normal dose. Titrate according to response.
- **APD/CAPD**: Not dialysed. Dose as in GFR<10 mL/ min.
- **HD**: Not dialysed. Dose as in GFR<10 mL/ min.
- **HDF/High flux**: Not dialysed. Dose as in GFR<10 mL/ min.
- **CAV/VVHD**: Not dialysed. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • IV injection: 20–50 75% of normal dose. Titrate according F – with spontaneous respiration: 50–200 mcg, then to response. 25–50 mcg as required. 10–20 75% of normal dose. Titrate according – with assisted ventilation: 0.3–3.5 mg, then 100–200 to response. mcg as required. <10 50% of normal dose. Titrate according • IV infusion: to response. – with spontaneous respiration: 3–4.8 micrograms/ kg/hour adjusted according to response. Dose in patients undergoing renal – with assisted ventilation: 10 mcg/kg over 10 minutes, replacement therapies then 6 mcg/kg/hour, may require up to 180 mcg/kg/ APD/CAPD Not dialysed. Dose as in GFR<10 mL/ hr during cardiac surgery. min. • Topical (chronic pain): Initially 12–25 mcg/hour, HD Not dialysed. Dose as in GFR<10 m...

---
## Phytomenadione (vitamin K) (Page 823)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
Dose in patients undergoing renal
P replacement therapies
APD/CAPD Unlikely to be dialysed. Dose as in
normal renal function.
HD Unlikely to be dialysed. Dose as in
normal renal function.
HDF/High flux Dialysed. Dose as in normal renal
function.
CAV/VVHD Unlikely to be dialysed. Dose as in
normal renal function.
• Antagonises effect of coumarins and phenindione.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. Dose in patients undergoing renal P replacement therapies APD/CAPD Unlikely to be dialysed. Dose as in normal renal function. HD Unlikely to be dialysed. Dose as in normal renal function. HDF/High flux Dialysed. Dose as in normal renal function. CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function. • Antagonises effect of coumarins and phenindione.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Other information 20–50 Dose as in normal renal function. • Konakion MM® recommended for severe haemorrhage. 10–20 Dose as in normal renal function. • Anticoagulation antidote: re-test prothrombin time <10 Dose as in normal renal function. 8–12 hours after Konakion®, 3 hours after Konakion MM® – repeat dose if inadequate. Dose in patients undergoing renal • Patients with obstructive jaundice requiring oral P replacement therapies vitamin K should be prescribed the water-soluble APD/CAPD Unlikely to be dialysed. Dose as in preparation menadiol sodium diphosphate – dosage normal renal function. range is similar. HD Unlikely to be dialysed. Dose as in normal renal function. HDF/High flux Dialysed. Dose as in normal renal function. CAV/VVHD Unlikely to be ...

---
## Dobutamine (Page 349)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Not dialysed. Dose as in normal renal function.
- **HD**: Not dialysed. Dose as in normal renal function.
- **HDF/High flux**: Not dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Not dialysed. Dose as in normal renal function. • Anaesthetics: risk of ventricular arrhythmias with isoflurane – avoid. • Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide. • Beta-blockers: possibly severe hypertension and bradycardia with non-cardioselective beta-blockers. • Dopaminergics: effects possibly enhanced by entacapone; avoid with rasagiline.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Care Group, Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, 3rd edition, 2006). 20–50 Dose as in normal renal function. 10–20 Dose as in normal renal function. Other information <10 Dose as in normal renal function. • Cardiac and BP monitoring advised. Dose in patients undergoing renal • Sodium bicarbonate rapidly inactivates dobutamine. replacement therapies • Solution may turn pink, but potency is unaffected. • Can cause hypokalaemia. APD/CAPD Not dialysed. Dose as in normal renal function. HD Not dialysed. Dose as in normal renal function. HDF/High flux Not dialysed. Dose as in normal renal function. CAV/VVHD Not dialysed. Dose as in normal renal function....

---
## Rupatadine (Page 919)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use
with caution.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. Use with caution.
- **APD/CAPD**: Unlikely to be dialysed. Dose as in R GFR<10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unknown dialysability. Dose as in GFR=10–20 mL/min. • Antibacterials: concentration increased by clarithromycin and erythromycin – use with caution. • Antifungals: concentration increased by itraconazole, ketoconazole, posaconazole and voriconazole – avoid; use fluconazole with caution. • Antivirals: concentration possibly increased by ritonavir and other protease inhibitors – avoid. • Grapefruit juice: concentration increased – avoid. • Lipid-lowering agents: use in combination with statins with caution. • Ciclosporin, sirolimus, tacrolimus – concentration possibly increased by rupatadine.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) 20–50 Dose as in normal renal function. Other information 10–20 Dose as in normal renal function. • Manufacturer contraindicates use due to lack of <10 Dose as in normal renal function. Use experience in renal impairment. with caution. Reference: 1. https://www.tga.gov.au/sites/default/files/auspar- Dose in patients undergoing renal rupafin.pdf replacement therapies APD/CAPD Unlikely to be dialysed. Dose as in R GFR<10 mL/min. HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min....

---
## Octreotide 729 (Page 748)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Unknown dialysability. Dose as in normal renal function.
- **HD**: Dialysed. Dose as in normal renal function.
- **HDF/High flux**: Dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Dialysed. Dose as in normal renal function. • Ciclosporin: ciclosporin concentration reduced.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Patients with reduced renal function have been shown to have a reduced clearance of the drug (75 20–50 Dose as in normal renal function. mL/min vs. 175 mL/min). 10–20 Dose as in normal renal function. <10 Dose as in normal renal function. Reference: 1. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic Dose in patients undergoing renal O applications in patients with pituitary tumours. Clin replacement therapies Pharmacokinet. 1993; 25(5): 375-91. APD/CAPD Unknown dialysability. Dose as in normal renal function. HD Dialysed. Dose as in normal renal function. HDF/High flux Dialysed. Dose as in normal renal function. CAV/VVHD Dialysed. Dose as in normal renal function....

---
## Phenelzine 793 (Page 812)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function.
- **APD/CAPD**: Possibly dialysed. Dose as in normal renal function.
- **HD**: Possibly dialysed. Dose as in normal renal function.
- **HDF/High flux**: Possibly dialysed. Dose as in normal renal function.
- **CAV/VVHD**: Unknown dialysability. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) rasagiline – avoid for at least 2 weeks after stopping MAOI; hypotension with selegiline. 20–50 Dose as in normal renal function. • 5HT agonist: risk of CNS toxicity with 10–20 Dose as in normal renal function. sumat 1 riptan, rizatriptan and zolmitriptan – avoid <10 Dose as in normal renal function. sumatriptan and rizatriptan for 2 weeks after MAOI. • Methyldopa: avoid concomitant use. Dose in patients undergoing renal • Opicapone: avoid concomitant use. replacement therapies • Sympathomimetics: hypertensive crisis with P sympathomimetics – avoid with methylphenidate. APD/CAPD Possibly dialysed. Dose as in normal • Tetrabenazine: risk of CNS excitation and renal function. hypertension avoid. HD Possibly dialysed. Dose as in normal renal function. Adm...

---
## Azacitidine 101 (Page 120)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function. See
'Other information'.
10–20 Dose as in normal renal function. See
'Other information'.
<10 Dose as in normal renal function. See
'Other information'.
APD/CAPD Unknown dialysability. Dose as in
GFR<10 mL/min.
HD Unknown dialysability. Dose as in
GFR<10 mL/min.
HDF/High flux Unknown dialysability. Dose as in
GFR<10 mL/min.
CAV/VVHD Unknown dialysability. Dose as in
GFR=10–20 mL/min.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function. See 'Other information'.
- **GFR 10–20**: Dose as in normal renal function. See 'Other information'.
- **GFR <10**: Dose as in normal renal function. See 'Other information'. APD/CAPD Unknown dialysability. Dose as in GFR<10 mL/min. HD Unknown dialysability. Dose as in GFR<10 mL/min. HDF/High flux Unknown dialysability. Dose as in GFR<10 mL/min. CAV/VVHD Unknown dialysability. Dose as in GFR=10–20 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • Clearance was 147 ± 47 L/hour. 20–50 Dose as in normal renal function. See • If unexplained reductions in serum bicarbonate levels 'Other information'. <20 mmol/L occur, the dose should be reduced by 10–20 Dose as in normal renal function. See 50% on the next cycle. If unexplained elevations in serum creatinine or BUN to ≥2-fold above baseline 'Other information'. values occur, the next cycle should be delayed until <10 Dose as in normal renal function. See values return to normal or baseline and the dose 'Other information'. should be reduced by 50% on the next treatment cycle. • Patients with renal impairment should be closely monitored for toxicity since azacitidine and/or its metabolites are primarily excreted by the kidney....

---
## Cefaclor (Page 195)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Dialysed. 250–500 mg every 8 hours.
HD Dialysed. 250–500 mg every 6–8
hours.
HDF/High flux Dialysed. 250–500 mg every 6–8
hours.
CAV/VVHD Dialysed. Dose as in normal renal
function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Dialysed. 250–500 mg every 8 hours. HD Dialysed. 250–500 mg every 6–8 hours. HDF/High flux Dialysed. 250–500 mg every 6–8 hours. CAV/VVHD Dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Rate of administration 20–50 Dose as in normal renal function. — 10–20 Dose as in normal renal function. <10 Dose as in normal renal function. Other information • Cefaclor is associated with protracted skin reactions....

---
## Bortezomib 135 (Page 154)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
Monitor carefully. See 'Other
information'.
<10 A reduced dose may be required.
Monitor carefully.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function. Monitor carefully. See 'Other information'.
- **GFR <10**: A reduced dose may be required. Monitor carefully.
- **APD/CAPD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HD**: Unlikely to be dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Unknown dialysability. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Unlikely to be dialysed. Dose as in GFR=10–20 mL/min. • Antibacterials: potential reduced efficacy with rifampicin resulting in increased monoclonal IgG λ – avoid.1 • Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) • There have been incidences of renal impairment, 20–50 Dose as in normal renal function. renal colic, proteinuria, dysuria, urinary frequency, 10–20 Dose as in normal renal function. urinary hesitation and haematuria. Monitor carefully. See 'Other • Anecdotally, has been used at normal doses in a information'. few haemodialysis patients; in some of the patients <10 A reduced dose may be required. platelet infusions have been required. Monitor carefully. • In patients with peripheral neuropathy then bortezomib has a high probability of exacerbating it. Dose in patients undergoing renal References: replacement therapies 1. Cuny P, Marfaing-Koka A, Lottmann M, et al. Drug interaction between bortezomib and tuberculosis APD/CAPD Unlikely to be dialysed. D...

---
## Ipratropium bromide (Page 555)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function.
APD/CAPD Not dialysed. Dose as in normal renal
function.
HD Not dialysed. Dose as in normal renal
function.
HDF/High flux Not dialysed. Dose as in normal renal
function.
CAV/VVHD Not dialysed. Dose as in normal renal
function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. APD/CAPD Not dialysed. Dose as in normal renal function. HD Not dialysed. Dose as in normal renal function. HDF/High flux Not dialysed. Dose as in normal renal function. CAV/VVHD Not dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) dilution is required. 20–50 Dose as in normal renal function. 10–20 Dose as in normal renal function. <10 Dose as in normal renal function....

---
## Trospium chloride (Page 1057)
### 1. Database (Raw Text)
```text
GFR (mL/min)
• Symptomatic treatment of urinary incontinence,
frequency or urgency
```
### 2. App Table View (Parsed)
- **APD/CAPD**: Probably dialysed. Dose as in GFR<10 mL/min.
- **HD**: Probably dialysed. Dose as in GFR<10 mL/min.
- **HDF/High flux**: Probably dialysed. Dose as in GFR<10 mL/min.
- **CAV/VVHD**: Probably dialysed. Dose as in GFR=10–30 mL/min.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) Antimuscarinic: 30–50 Dose as in normal renal function. • Symptomatic treatment of urinary incontinence, 10–30 20 mg daily or on alternate days. See frequency or urgency 'Other information'. <10 20 mg daily or on alternate days. See Dose in normal renal function 'Other information'. • 20 mg twice daily Dose in patients undergoing renal • XL: 60 mg once daily replacement therapies Pharmacokinetics APD/CAPD Probably dialysed. Dose as in GFR<10 mL/min. Molecular weight (daltons) 428 HD Probably dialysed. Dose as in GFR<10 % Protein binding 50–80 mL/min. % Excreted unchanged in urine 5.8 HDF/High flux Probably dialysed. Dose as in GFR<10 Volume of distribution (L/kg) 395 Litres / XL: mL/min. >600 Litres CAV/VVHD Probably dialysed. Dose as in Half-life — no...

---
## Dasatinib 291 (Page 310)
### 1. Database (Raw Text)
```text
GFR (mL/min)
20–50 Dose as in normal renal function.
10–20 Dose as in normal renal function.
<10 Dose as in normal renal function. Use
with caution.
APD/CAPD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
D
HD Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
HDF/High flux Unlikely to be dialysed. Dose as in
GFR<10 mL/min.
CAV/VVHD Unlikely to be dialysed. Dose as in
normal renal function.
```
### 2. App Table View (Parsed)
- **GFR 20–50**: Dose as in normal renal function.
- **GFR 10–20**: Dose as in normal renal function.
- **GFR <10**: Dose as in normal renal function. Use with caution. APD/CAPD Unlikely to be dialysed. Dose as in GFR<10 mL/min. D HD Unlikely to be dialysed. Dose as in GFR<10 mL/min. HDF/High flux Unlikely to be dialysed. Dose as in GFR<10 mL/min. CAV/VVHD Unlikely to be dialysed. Dose as in normal renal function.

### 3. Original PDF Context (Snippet)
> ...Dose in renal impairment GFR (mL/min) impairment but due to the low renal excretion there is unlikely to be a reduction in clearance. 20–50 Dose as in normal renal function. • Most common adverse effects of dasatinib include 10–20 Dose as in normal renal function. fluid retention, gastrointestinal disturbances, and <10 Dose as in normal renal function. Use bleeding. Fluid retention may be severe, and can with caution. result in pleural and pericardial effusion, pulmonary oedema and ascites....

---
